Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Peer support and Hepatitis C Treatment


Published on

  • Be the first to comment

Peer support and Hepatitis C Treatment

  1. 1. Peer Advocacy Stephanie Broughton, BBV CNS Ala Miah, Peer mentor
  2. 2. Groundswell Homeless Health Peer Advocacy (HHPA) •Peer Advocates offer one-to-one support for people experiencing homelessness to make and attend health appointments, and overcome the barriers which prevent them from addressing their health needs. •“HHPA reduces the use of A&E, missed appointments and unplanned admissions…” (Young Foundation HHPA Evaluation 2014).
  3. 3. HALT Hepatitis study hypothesis : Providing peer support and accompanied referrals to hard-to-reach individuals (homeless or substance misusing) infected with hepatitis B (HBV) or C (HCV) virus will increase likelihood of a full diagnosis and treatment completion… (Randomised controlled trial, U.C.L & Department of Health)
  4. 4. • Recruit HCV +ve’s, either via screening or harvesting known positives from drug treatment services and hostels. • Randomise to receive either: o Normal care – a referral to secondary care o Intervention – a referral to secondary care with support from a peer from Groundswell. • Allocation of those infected with HBV to peer support and accompanied referrals.
  5. 5. Peers meet with the patient, chase/re-arrange appointments, accompany them to hospital, take them to other health related appointments, advocate on their behalf etc.
  6. 6. Primary outcomes: 1. Cost effectiveness evaluation of outcomes. 2. Successfully reaching an appropriate clinical endpoint for those infected with hepatitis C.
  7. 7. Secondary outcomes: 1. Sustained virological response to HCV treatment. 2. Successfully reaching an appropriate clinical endpoint, full diagnosis and commencement of treatment, where appropriate, for those HBV infected. 3. Proportion of hard-to-reach with adequate immune response to HBV vaccine. 4. Factors influencing lack of vaccine uptake.